DUBLIN–(BUSINESS WIRE)–The “Cell Based Assay & High Content Screening Markets 2022 to 2026: Forecasts by User and Product. With Executive and Consultant Guides. including Customized Forecasting and Analysis. “ report has been added to ResearchAndMarkets.com’s providing.
Cell Primarily based Assays are a mainstay of drug improvement and scientific analysis, and now, publish pandemic, analysis exercise is taking off. On prime of this new expertise is permitting Cell Primarily based Assays for use to measure any side of cell operate.
This market simply retains on rising for ever and ever. The workhorse of the pharmaceutical trade is turning into a central participant in biotechnology.
This can be a complicated space however this report will carry the whole administration crew in control, on each the expertise and the chance. The expertise is transferring quicker than the market. Genomics and Immunology are taking part in a job too. Discover the alternatives and the pitfalls. Perceive development expectations and the final word potential market dimension.
Key Matters Lined:
1. Market Guides
- Scenario Evaluation
- Information for Executives and Advertising Employees
- Information for Funding Analysts and Administration Consultants
2. Introduction and Market Definition
- What are Cell Primarily based Assays?
- Scientific Trial Failures
- Immuno-oncology Performs a Main Position in Cell Primarily based Assays
- Infectious Illness Will Play a Bigger Position
- .4 Market Definition
- Methodology
- U.S. Medical Market and Pharmaceutical Analysis Spending -Perspective
3. Cell Primarily based Assays – Information to Know-how
- Cell Cultures
- Cell Assays
- Cell Viability Assays
- Cell Proliferation Assays
- Cytotoxicity Assays
- Cell Senescence Assays
- Apoptosis
- Autophagy
- Necrosis
- Oxidative Stress
- 2D vs. 3D
- Signalling Pathways, GPCR
- Immune Regulation & Inhibition
- Reporter Gene Know-how
- CBA Design & Growth
- Cell Primarily based Assays – The Takeaway
4. Trade Overview
-
Gamers in a Dynamic Market
- Tutorial Analysis Lab
- Contract Analysis Group
- Genomic Instrumentation Provider
- Cell Separation and Viewing Provider
- Cell Line and Reagent Provider
- Pharmaceutical Firm
- Audit Physique
- Certification Physique
5. Market Traits
-
Components Driving Progress
- Candidate Progress
- Immuno-oncology
- Genomic Blizzard
- Know-how Convergence
- The Insurance coverage Impact
-
Components Limiting Progress
- CBA Growth Challenges
- Instrument Integration
- Protocols
-
Know-how Growth
- 3D Assays
- Automation
- Software program
- Main Cells
- Signaling and Reporter Genes
- The Subsequent 5 Years
6. Cell Primarily based Assays Current Developments
- Current Developments – Significance and The best way to Use This Part
- Nanolive closes a USD 20 million Funding Spherical
- Depixus Seeks to Commercialize ‘Magnetic Tweezers’ for Drug Discovery
- BioAuxilium Analysis Expands its Cell Signaling Assay Portfolio
- Droplet Genomics Debuts New Microfluidic Screening Platform
- DLP Plus Single-Cell Sequencing Technique Spreads From Canada to Most cancers Labs Worldwide
- Secondcell Bio to Make Creation of Cell Traces Straightforward
- Nanolitre-scale cell assays developed with droplet microarray mass spec
- Thermo Fisher Scientific Acquires Cell Sorting Know-how
- Cellink to Distribute Phasefocus Excessive-Content material Cell Imaging Platform
- Axxam and FUJIFILM Mobile Dynamics Announce Strategic Alliance
- Most cancers Genetics to Purchase Organoid Startup Stemonix
- Curi Bio Acquires Synthetic Intelligence Agency Dana Options
- CRISPR Screens Uncover Novel Most cancers Remedy Targets
- ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam
- New Transcriptomics Assay Facilitates Compound Screens
- Carta Biosciences Betting on Gene Interplay Mapping
- Excessive-throughput Identifies most cancers drug candidates
- Velabs Therapeutics companions with Alytas Therapeutics to develop a novel immune-based remedy for weight problems
- InSphero platform chosen to check Cyclerion’s sGC stimulator expertise
- OcellO to offer in vitro analysis providers to Merus
- Charles River Laboratories to amass Citoxlab
- Response Biology Company Purchases ProQinase GmbH
7. Profiles of Key Cell Primarily based Assay Corporations
- Abcam
- Agilent
- Aurora Devices Ltd.
- Axxam
- Beckman Coulter Diagnostics
- Becton, Dickinson and Firm
- BioIVT
- Bio-Rad Laboratories, Inc.
- BioTek Devices
- BioVision, Inc.
- BMG Labtech
- Cell Biolabs, Inc.
- Cell Signaling Know-how, Inc.
- Charles River Laboratories
- Cisbio Bioassays
- Corning, Inc.
- Cytovale
- Enzo Life Sciences, Inc.
- Eurofins DiscoverX Company
- Evotec AG
- Excellerate Bioscience
- Fujifilm Mobile Dynamics Worldwide
- Genedata
- Hemogenix
- Horizon Discovery
- Invivogen
- Leica Biosystems
- Lonza Group Ltd.
- Luminex Corp
- Merck & Co., Inc
- Miltenyi Biotec
- Molecular Units
- Nanion
- Ncardia
- New England Biolabs, Inc.
- Olympus
- Origene Applied sciences
- Perkin Elmer
- Promega
- Qiagen Gmbh
- Response Biology
- Recursion Pharma
- Roche Diagnostics
- Sartorius
- Sartorius-ForteBio
- Sartorius-IntelliCyt
- Sony Biotechnology
- SPT Labtech
- Stemcells Applied sciences Canada Inc.
- Tecan
- Thermo Fisher Scientific Inc.
- Vitro Biopharma
8. World Market Dimension
- World Market Overview by Nation
- World Market by Person – Overview
- World Market by Product Class – Overview
9. World Market by Person Kind
- Pharma
- Analysis
- Trade/Beauty
10. Cell Primarily based Assay by Product Class
- Instrument
- Reagent
- Companies
- Software program
11. Appendices
- FDA Most cancers Drug Approvals by Yr
- Scientific Trials Began 2010 to 2016
- Share of Pharma R&D by Nation
For extra details about this report go to https://www.researchandmarkets.com/r/ki03vo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s main supply for worldwide market analysis stories and market information. We give you the newest information on worldwide and regional markets, key industries, the highest corporations, new merchandise and the newest tendencies.
